Publications

Detailed Information

Performance Evaluation of the GlucoDr Plus Glucometer

DC Field Value Language
dc.contributor.authorKo, Dae-Hyun-
dc.contributor.authorLim, Soo-
dc.contributor.authorChoi, Sung Hee-
dc.contributor.authorSong, Sang Hoon-
dc.contributor.authorPark, Young Joo-
dc.contributor.authorJang, Hak Chul-
dc.contributor.authorSong, Junghan-
dc.contributor.authorPark, Kyoung Un-
dc.date.accessioned2012-06-25T08:35:06Z-
dc.date.available2012-06-25T08:35:06Z-
dc.date.issued2010-04-
dc.identifier.citationDIABETES TECHNOLOGY & THERAPEUTICS; Vol.12 4; 307-312ko_KR
dc.identifier.issn1520-9156-
dc.identifier.urihttps://hdl.handle.net/10371/77401-
dc.description.abstractBackground: Because strict glucose control is important for reducing the complications of diabetes, the self-monitoring of blood glucose is one of the fundamental treatment modalities. Many glucometers have been developed. In the present study, we evaluated a new glucometer: GlucoDr (TM) Plus (Allmedicus, Anyang, Gyeonggi-do, Republic of Korea). Methods: The evaluation was performed based on Clinical and Laboratory Standards Institute guidelines. Interferences by ascorbic acid, uric acid, maltose, and acetaminophen were examined, and the performance of the unit was compared to those of six other glucometers. The effects of hematocrit, of oxygen partial pressure (PaO(2)), and of multiple users were also evaluated. Results: Within-run, between-run, between- day, and total imprecision (coefficients of variation) were 0.99-4.98%. Satisfactory linearity was found for glucose concentrations of 32.5-786.5 mg/dL (R(2) = 0.9985). A comparison with the reference laboratory method showed close concordance over the entire range of concentrations evaluated (R(2) = 0.9869). No significant effects were noted due to added interferents, hematocrit, and PaO(2). Conclusions: The GlucoDr Plus showed acceptable performance in terms of precision and linearity. It was minimally affected by various interferents. GlucoDr Plus is suitable for the self-monitoring of blood glucose by patients with diabetes.ko_KR
dc.language.isoenko_KR
dc.publisherMARY ANN LIEBERT INCko_KR
dc.titlePerformance Evaluation of the GlucoDr Plus Glucometerko_KR
dc.typeArticleko_KR
dc.contributor.AlternativeAuthor고대현-
dc.contributor.AlternativeAuthor최성희-
dc.contributor.AlternativeAuthor박경운-
dc.contributor.AlternativeAuthor송정한-
dc.contributor.AlternativeAuthor장학철-
dc.contributor.AlternativeAuthor박영주-
dc.contributor.AlternativeAuthor송상훈-
dc.contributor.AlternativeAuthor임수-
dc.identifier.doi10.1089/dia.2009.0134-
dc.citation.journaltitleDIABETES TECHNOLOGY & THERAPEUTICS-
dc.description.citedreferenceSchleis TG, 2007, PHARMACOTHERAPY, V27, P1313-
dc.description.citedreferenceTsujimura S, 2006, BIOSCI BIOTECH BIOCH, V70, P654-
dc.description.citedreferenceD`Orazio P, 2006, CLIN CHEM LAB MED, V44, P1486, DOI 10.1515/CCLM.2006.275-
dc.description.citedreferenceNathan DM, 2005, NEW ENGL J MED, V353, P2643-
dc.description.citedreferenceWild S, 2004, DIABETES CARE, V27, P1047-
dc.description.citedreference*CLIN LAB STAND I, 2004, EP5A2 CLSI-
dc.description.citedreference*CLIN LAB STAND I, 2003, EP6A CLSI-
dc.description.citedreference*INT ORG STAND, 2003, 151972003E ISO-
dc.description.citedreference*CLIN LAB STAND I, 2002, EP7A CLIS-
dc.description.citedreferenceTang ZP, 2001, CRIT CARE MED, V29, P1062-
dc.description.citedreferenceTang ZP, 2000, AM J CLIN PATHOL, V113, P75-
dc.description.citedreferenceTurner RC, 1998, LANCET, V352, P837-
dc.description.citedreference*CLIN LAB STAND I, 1995, EP9A CLSI-
dc.description.citedreference1994, DIABETES CARE, V17, P81-
dc.description.citedreferenceMERENSTEIN GB, 1993, PEDIATRICS, V92, P474-
dc.description.citedreference1993, N ENGL J MED, V329, P977-
dc.description.citedreferenceBARRETT AE, 1979, J CLIN PATHOL, V32, P893-
dc.description.tc0-
Appears in Collections:
Files in This Item:

Altmetrics

Item View & Download Count

  • mendeley

Items in S-Space are protected by copyright, with all rights reserved, unless otherwise indicated.

Share